Nemolizumab-ilto (Nemluvio) is an interleukin-31 receptor antagonist. Nemluvio was first approved in August 2024 for adults with prurigo nodularis. Later that year, in December, Nemluvio received an expanded indication for the treatment of atopic dermatitis in adults and pediatric patients 12 years and older.
Read on to learn more about Nemluvio, including its warnings and precautions, dosage and administration information, and more.
Medication Overview:
- Brand Name: Nemluvio
- Generic Name: nemolizumab-ilto
- Treatment for: Prurigo nodularis, atopic dermatitis
- Company: Galderma
- Initial FDA Approval: August 2024
| Indicated Condition | Indication | Age | Date Approved |
|---|---|---|---|
| Prurigo Nodularis | Indicated for the treatment of adults with prurigo nodularis. | Adults | August 2024 |
| Atopic Dermatitis | Indicated for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. | Adults and pediatric patients 12 and older. | December 2024 |
Warnings and Precautions:
- Hypersensitivity: Hypersensitivity reactions have been reported with Nemluvio use. If a clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy and discontinue Nemluvio.
- Vaccinations: Avoid use of live vaccines during treatment with Nemluvio.
Dosage and Administration:
Complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to treatment with Nemluvio.
Prurigo Nodularis:
- Adult Patients Weighing Less Than 90kg: The recommended subcutaneous dosage is an initial dose of 60 mg (two 30 mg injections), followed by 30 mg given every 4 weeks.
- Adult Patients Weighing 90kg or More: The recommended subcutaneous dosage is an initial dose of 60 mg (two 30 mg injections), followed by 60 mg given every 4 weeks.
Atopic Dermatitis:
- The recommended subcutaneous dosage is an initial dose of 60 mg (two 30 mg injections), followed by 30 mg given every 4 weeks.
- After 16 weeks of treatment, for patients who achieve clear or almost clear skin, a dosage of 30 mg every 8 weeks is recommended.
- Use Nemluvio with topical corticosteroids and/or topical calcineurin inhibitors. When the disease has sufficiently improved, discontinue use of topical therapies.
- Administer Nemluvio by subcutaneous injection.
- Nemluvio must be reconstituted prior to administration.
Contraindications:
Known hypersensitivity to nemolizumab-ilto or to any of the excipients in Nemluvio.
Adverse Reactions:
Most common adverse reactions are:
- Prurigo nodularis (incidence ≥1%): headache, dermatitis atopic, eczema, and eczema nummular.
- Atopic dermatitis (incidence ≥1%): headache (including migraine), arthralgia, urticaria, and myalgia.
Please note: This article is current as of June 18, 2026. Consult our clinical guidelines library or drug information tool to ensure you always have the most up-to-date information.
Sign up for alerts to keep up with the latest clinical guidelines and guideline updates.